Eli Lilly To Rally Over 21%? Here Are 10 Top Analyst Forecasts For Thursday
Key takeaways
- The move comes after the company’s latest earnings beat expectations and its guidance for the next quarter remains strong.
- Price target increased from $1,410 to $1,440
- Earnings beat estimates
- Revenue grew 7% YoY
What happened
The move comes after the company’s latest earnings beat expectations and its guidance for the next quarter remains strong.
Why it matters
The new target reflects confidence that Lilly’s drug pipeline and sales momentum will drive higher revenue and earnings. A $30 lift on a $1,400 base represents a 2.1% upside, suggesting analysts see room for upside in the near term.
Short-term and longer-term
Short-term. Over the next few days, LLY could see a short‑term rally as traders react to the upgraded target.
Longer-term. For investors, the upgrade suggests that Lilly’s pipeline and sales trajectory justify a higher valuation.